Financial Reports Latest Updates Industry Maps Economic Calendar

Aurinia Pharmaceuticals Inc. (AUPH) Annual Reports

Q: Where can I read Aurinia Pharmaceuticals Inc. (AUPH) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Aurinia Pharmaceuticals Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1600620 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$83.2M	$70.0M	+18.9%
Operating income	$46.3M	$20.1M	+130.7%
Net income	$37.4M	$21.5M	+73.9%
EPS (diluted)	$0.28	$0.16	+75.0%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 83.2 mn Net income 37.4 mn

Show table：Income statement

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0.01	0	0.46	0.03	0.03	0.23	0.03	0.03	0.03	0.03	50.0	0.91	6.62	14.7	23.4	21.6	28.2	55.8	28.4	34.4	41.5	54.5	45.1	50.3	57.2	67.8	59.9	62.5	70.0	73.5	77.1	77.7	83.2
Operating income	-25.0	-46.9	-54.1	-14.9	-17.1	-24.1	-34.8	-27.1	-26.9	-42.3	-8.05	-50.5	-47.1	-50.4	-32.7	-37.9	-36.0	-9.50	-28.1	-29.6	-16.2	-16.3	-29.7	-13.3	-1.51	11.8	-1.67	21.9	20.1	29.8	33.2	41.4	46.3
Net income	-23.3	-70.8	-64.1	-14.1	-16.4	-23.4	-34.5	-25.9	-26.5	-42.1	-8.07	-50.4	-47.0	-50.3	-33.3	-37.6	-35.5	-8.99	-26.1	-26.2	-11.5	-13.4	-26.9	-10.8	0.72	14.3	1.43	23.3	21.5	31.6	211	34.4	37.4

Balance sheet

Quarterly · In mn (USD)

Total assets 792 mn Total liabilities 177 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	41.4	175	133	—	—	—	315	—	—	—	419	372	350	329	513	478	453	460	443	424	416	426	425	398	410	440	447	406	409	439	492	480	541
Total assets	57.0	190	146	—	—	—	327	—	—	—	464	417	386	360	543	507	482	488	471	452	549	555	548	517	524	549	551	505	503	528	752	724	792
Current liabilities	7.93	8.15	7.26	—	—	—	11.3	—	—	—	32.0	21.1	29.3	37.5	40.6	33.8	34.6	41.8	46.1	42.0	61.7	73.9	77.2	71.0	76.9	78.6	97.8	68.4	78.3	76.2	93.7	86.6	99.9
Total liabilities	21.1	24.1	33.3	—	—	—	53.2	—	—	—	55.9	46.9	54.0	61.9	64.3	58.8	58.4	64.9	65.4	61.4	157	163	170	157	159	161	173	155	167	162	170	156	177
Equity	36.0	166	113	—	—	—	274	279	258	409	408	370	332	298	479	448	424	423	405	390	392	392	378	359	365	388	377	350	335	366	581	568	615

Cash flow

Quarterly · In mn (USD)

Operating 52.6 mn Investing 81.5 mn Financing 4.81 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-18.7	-41.2	-51.6	—	—	—	-63.5	-22.6	-22.0	-28.4	3.20	-53.5	-38.0	-40.3	-25.9	-46.8	-27.9	-15.4	10.4	-31.7	-2.83	-13.3	14.3	-18.6	15.8	17.0	30.1	1.30	44.2	44.5	45.7	32.6	52.6
Investing	9.99	-8.00	-0.07	—	—	—	7.78	-12.1	-20.7	-144	19.1	-67.3	1.67	-32.8	-5.49	-53.0	45.6	-50.2	-3.02	24.9	-5.61	-19.7	-6.26	49.2	-38.6	-10.6	39.2	31.0	-13.3	-13.8	-36.8	-18.1	81.5
Financing	42.6	175	4.01	—	—	—	244	2.92	0.95	189	1.24	5.03	1.28	9.08	206	0.41	1.34	0	0.69	1.64	1.14	-2.33	-5.58	-15.1	-8.27	-2.72	-23.1	-49.3	-44.4	-10.5	-1.89	-53.7	4.81
Cash at period end	39.6	166	118	—	—	—	306	274	232	249	272	157	122	57.6	232	132	151	85.3	94.1	88.3	81.4	45.6	48.8	63.9	33.3	36.6	83.4	66.1	52.9	72.9	80.2	40.8	180

Profitability

Quarterly · %

Operating margin 55.7% Net margin 45.0%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	-500540.0%	-2343400.0%	-11683.1%	-49636.7%	-59113.8%	-10464.4%	-120141.4%	-90200.0%	-92631.0%	-145913.8%	-16.1%	-5529.9%	-712.0%	-343.3%	-139.7%	-175.2%	-127.7%	-17.0%	-98.8%	-86.0%	-39.0%	-29.8%	-65.8%	-26.4%	-2.6%	17.3%	-2.8%	35.0%	28.7%	40.5%	43.1%	53.3%	55.7%
Net margin	-465900.0%	-3539600.0%	-13848.8%	-46990.0%	-56465.5%	-10197.4%	-118824.1%	-86440.0%	-91531.0%	-145275.9%	-16.1%	-5511.9%	-710.1%	-342.6%	-142.4%	-174.0%	-126.0%	-16.1%	-91.6%	-76.2%	-27.7%	-24.7%	-59.6%	-21.4%	1.3%	21.2%	2.4%	37.4%	30.7%	43.0%	273.4%	44.2%	45.0%

Returns & leverage

Quarterly · %

ROE 66.1% ROA 48.5% Debt ratio 22.4%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	-45.8%	-35.9%	-42.8%	-31.5%	-30.1%	-39.2%	-50.0%	-44.0%	-40.8%	-41.1%	-41.5%	-32.0%	-24.5%	-23.1%	-17.8%	-18.9%	-19.9%	-16.7%	-13.3%	-5.8%	1.5%	11.2%	17.3%	20.6%	59.9%	65.0%	66.1%
ROA	—	—	—	—	—	—	-37.4%	—	—	—	-26.0%	-30.5%	-38.2%	-43.3%	-35.9%	-36.4%	-36.1%	-27.2%	-21.3%	-20.2%	-14.1%	-14.8%	-15.3%	-12.9%	-9.4%	-4.1%	1.1%	7.8%	11.8%	14.5%	44.1%	48.5%	48.5%
Debt ratio	36.9%	12.7%	22.8%	—	—	—	16.3%	—	—	—	12.1%	11.2%	14.0%	17.2%	11.8%	11.6%	12.1%	13.3%	13.9%	13.6%	28.5%	29.4%	31.0%	30.4%	30.4%	29.4%	31.4%	30.6%	33.3%	30.7%	22.6%	21.6%	22.4%

EPS

Quarterly · US$

EPS US$0.28

Show table：EPS

Item	2016Q4	2017Q4	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	-0.95	-0.23	-0.24	-0.34	-0.06	-0.40	-0.37	-0.39	-0.25	-0.27	-0.25	-0.06	-0.18	-0.18	-0.08	-0.09	-0.19	-0.07	0.01	0.10	0.01	0.16	0.16	0.23	1.53	0.25	0.28

Revenue & profit

Year-to-date · In mn (USD)

Revenue 161 mn Net income 71.8 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 792 mn Total liabilities 177 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating 85.1 mn Investing 63.4 mn Financing -48.9 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin 54.5% Net margin 44.6%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE 66.1% ROA 48.5% Debt ratio 22.4%

EPS

Year-to-date · US$

EPS US$0.53

Revenue & profit

Annual · In mn (USD)

Revenue 283 mn Net income 287 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2019	2020	2021	2022	2023	2024	2025
Revenue	0.32	50.1	45.6	134	176	235	283
Operating income	-90.9	-104	-181	-111	-91.7	-4.69	105
Net income	-88.4	-103	-181	-108	-78.0	5.75	287

Balance sheet

Annual · In mn (USD)

Total assets 752 mn Total liabilities 170 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2019	2020	2021	2022	2023	2024	2025
Current assets	315	419	513	443	425	447	492
Total assets	327	464	543	471	548	551	752
Current liabilities	11.3	32.0	40.6	46.1	77.2	97.8	93.7
Total liabilities	53.2	55.9	64.3	65.4	170	173	170
Equity	274	408	479	405	378	377	581

Cash flow

Annual · In mn (USD)

Operating 136 mn Investing -32.8 mn Financing -106 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2019	2020	2021	2022	2023	2024	2025
Operating	—	-69.9	-158	-79.5	-33.5	44.4	136
Investing	—	-158	-104	-60.6	-6.71	39.3	-32.8
Financing	—	194	221	2.43	-5.13	-49.1	-106
Cash at period end	306	272	232	94.1	48.8	83.4	80.2

Profitability

Annual · %

Operating margin 37.1% Net margin 101.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2019	2020	2021	2022	2023	2024	2025
Operating margin	-28598.4%	-208.1%	-396.3%	-83.2%	-52.2%	-2.0%	37.1%
Net margin	-27794.0%	-204.9%	-396.8%	-80.7%	-44.5%	2.5%	101.5%

Returns & leverage

Annual · %

ROE 59.9% ROA 44.1% Debt ratio 22.6%

Show table：Returns & leverage

Item	2019	2020	2021	2022	2023	2024	2025
ROE	-32.3%	-30.1%	-40.8%	-24.5%	-19.9%	1.5%	59.9%
ROA	-27.1%	-26.0%	-35.9%	-21.3%	-15.3%	1.1%	44.1%
Debt ratio	16.3%	12.1%	11.8%	13.9%	31.0%	31.4%	22.6%

EPS

Annual · US$

EPS US$2.08

Show table：EPS

Item	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	-0.87	-1.41	-0.76	-0.54	0.05	2.08

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Aurinia Pharmaceuticals Inc. (AUPH) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.